8-Cedren-13-ol is a niche cedrane-type sesquiterpene alcohol with a much thinner public evidence base than better-known aroma constituents. The strongest support in this research pass is for chemical identity and occurrence in sesquiterpene-rich plant materials such as costus root oil, Santolina flower extracts, and Artemisia arborescens essential oil. I did not verify direct isolated-constituent human or robust pharmacology literature for 8-cedren-13-ol itself, so this record should stay focused on identity, occurrence, and explicit evidence gaps rather than wellness-style claims.
Chemical identity and composition
PubChem resolved the queried name 8-Cedren-13-ol to CID 519545 under the title Npc136555 and returned synonyms including 8-cedren-13-ol, Cedr-8-en-13-ol, and Cedren-13-ol, 8-. The local archive already uses this constituent in costus root oil at 5.06%. Current public literature places it inside cedrane-skeleton sesquiterpenoid fractions, but accessible sources reviewed in this pass did not provide a directly readable confirmed CAS number.
Aroma and practical use
- Use the recorded woody, cedar-like, dry, sesquiterpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2012 Saussurea lappa root-oil study identified 8-cedren-13-ol at 5.06% among the principal oil constituents, but the isolated larvicidal actives reported from the same work were dehydrocostus lactone and costunolide rather than 8-cedren-13-ol.
A 2012 Saussurea lappa root-oil study identified 8-cedren-13-ol at 5.06% among the principal oil constituents, but the isolated larvicidal actives reported from the same work were dehydrocostus lactone and costunolide rather than 8-cedren-13-ol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 Santolina chamaecyparissus profiling study reported that sesquiterpenoids were the major fraction of the flower extract and specifically noted cedrane-skeleton compounds represented by 8-cedren-13-ol within a mixture showing antifungal activity against Neocosmospora species.
A 2025 Santolina chamaecyparissus profiling study reported that sesquiterpenoids were the major fraction of the flower extract and specifically noted cedrane-skeleton compounds represented by 8-cedren-13-ol within a mixture showing antifungal activity against Neocosmospora species.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2024 Artemisia arborescens essential-oil paper listed 8-cedren-13-ol among the main components in an oil with phytotoxic and antimicrobial activity, but it did not isolate 8-cedren-13-ol as the causal agent.
A 2024 Artemisia arborescens essential-oil paper listed 8-cedren-13-ol among the main components in an oil with phytotoxic and antimicrobial activity, but it did not isolate 8-cedren-13-ol as the causal agent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot assessed
Not assessed in the available record.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific dermal limit, sensitization study, or human tolerability paper for isolated 8-cedren-13-ol was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because currently accessible evidence is dominated by occurrence papers and mixture-level studies, archive copy should avoid implying validated therapeutic or safety outcomes for isolated 8-cedren-13-ol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
no_constituent_specific_mechanism_verified
No isolated-constituent molecular target or human pharmacology for 8-cedren-13-ol was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- A directly readable public CAS confirmation for 8-cedren-13-ol was not verified in this pass.
- No isolated-constituent human clinical, animal efficacy, or mechanistic pharmacology study for 8-cedren-13-ol itself was verified in the reviewed public sources.
- Most accessible literature mentions 8-cedren-13-ol only as part of complex essential-oil or extract mixtures.
- No RIFM/IFRA safety assessment or dermal-limit source specific to 8-cedren-13-ol was located in this pass; because identity itself is unconfirmed against a distinct CAS number, the record was not merged with the separate cedrenol.json entry despite a shared listed CAS. dermal_limit_pct and sensitizing were corrected from unsourced placeholders to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.